BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Rhea-AI Summary

BriaCell (Nasdaq: BCTX) will present clinical and preclinical data at the 2025 San Antonio Breast Cancer Symposium (SABCS), Dec 9–12, 2025. The company announced three clinical posters and one preclinical poster, including two late-breaking clinical posters reporting updated biomarker and survival data from its Phase 3 Bria-ABC trial and Phase 2 Bria-IMT study in metastatic breast cancer.

All posters are scheduled for Wednesday, Dec 10, 2025; poster copies will be available at https://briacell.com/scientific-publications/ after presentation.

Insights

Clinical Immuno-oncology Analyst

Presentation of Phase 2 and pivotal Phase 3 clinical data at SABCS is noteworthy but outcome-agnostic until results are disclosed.

BriaCell has secured three clinical posters, including two late-breaking entries, to present updated biomarker and survival data tied to the Phase 3 Bria-ABC trial and the Phase 2 Bria-IMT program at SABCS on December 9-12, 2025. Public presentation of biomarker correlations and survival readouts exposes the programs to specialist scrutiny and could accelerate scientific validation if the data show clear signals. The company will publish posters after the sessions, enabling independent review.

The announcement alone provides no numeric outcomes, so impact remains uncertain. Key dependencies include the actual effect sizes, statistical significance, and reproducibility of biomarker–outcome relationships presented on December 10, 2025. Risks include interpretation by the clinical community and whether the data meet pivotal endpoints or alter the trial conduct; without disclosed results, neither positive nor negative conclusions are justified. Watch for the two late-breaking posters (Abstracts 3688 and 3713) and the survival and biomarker metrics released immediately after the presentations within the same week for an informed re-assessment over the following days to weeks.

• Three BriaCell poster presentations include updated key biomarker data from BriaCell’s pivotal Phase 3 study and updated survival data from the Phase 2 study of Bria-IMT™ plus immune check point inhibitor (CPI) in metastatic breast cancer
  

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS^®) taking place from December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, Texas.

“With three poster presentations, including two potentially high impact late-breaking clinical posters, we will be presenting significant amounts of data to the most prominent breast cancer scientific experts and cancer specialists as we advance our therapies with the goal of developing better clinical outcomes for cancer patients,” stated William V. Williams, MD, BriaCell’s President & CEO.

The details of the poster presentations are listed below.

Late-Breaking Abstract Number: 3688
Presentation Number: PS1-13-22
Presentation Title: Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial
Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM - 2:00 PM

Late-Breaking Abstract Number: 3713
Presentation Number: PS1-13-23
Presentation Title: Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM - 2:00 PM

Abstract Number: 1614
Presentation Number: PS2-09-03
Presentation Title: Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer.
Poster Presentation Date/Time: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM

Following the presentation, copies of the posters will be made available at https://briacell.com/scientific-publications/.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about presenting three posters at the 2025 SABCS, and the contents of such posters, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com

FAQ

What data will BriaCell (BCTX) present at SABCS 2025?

BriaCell will present updated biomarker data from the Phase 3 Bria-ABC trial and updated survival data from the Phase 2 Bria-IMT study, plus a preclinical SV-BR-1-GM biomarker poster.

When and where will BriaCell (BCTX) present its SABCS 2025 posters?

BriaCell's posters are scheduled for Wednesday, December 10, 2025 at the San Antonio Breast Cancer Symposium (Henry B. Gonzalez Convention Center, San Antonio, TX).

Which BriaCell abstracts are late-breaking at SABCS 2025?

Late-breaking abstracts are 3688 (Bria-ABC Phase 3 biomarkers) and 3713 (Phase 2 Bria-IMT survival results).

How can investors access BriaCell's SABCS 2025 posters after the presentations?

Poster copies will be posted at https://briacell.com/scientific-publications/ following the presentations.

What is the focus of BriaCell's poster on SV-BR-1-GM at SABCS 2025?

The SV-BR-1-GM poster (abstract 1614) reports Th1-biased cytokine signatures as biomarkers of clinical benefit after cancer vaccination in breast cancer.